Phase 1 Trial of Intravenously Administered Nerofe™ in Subjects With Advanced Malignancies

Summary

This study will be the first to test the anti-cancer peptide Nerofe in humans. It will evaluate the safety, pharmacokinetic behavior, and pharmacodynamic and clinical effects of Nerofe given intravenously every other day to patients with advanced malignant disease.

Timeline

Start

2013-12

Primary completion

2017-12-19

Completion

2017-12-19

Publications

• Background Sandler U, Devary O, Braitbard O, Ohana J, Kass G, Rubinstein AM, Friedman ZY, Devary Y. NEROFE--a novel human hormone-peptide with anti-cancer activity. J Exp Ther Oncol. 2010;8(4):327-39.

Drugs

Indications